<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00931879</url>
  </required_header>
  <id_info>
    <org_study_id>LVZ111903</org_study_id>
    <nct_id>NCT00931879</nct_id>
  </id_info>
  <brief_title>Lovaza® and Microvascular Function in Type 2 Diabetes</brief_title>
  <official_title>The Role of Lovaza® on Microvascular Function and Lipoprotein Profile in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Virginia Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Virginia Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the efficacy of 6 months of 4 g/day oral Lovaza®
      on endothelial-dependent and heat-induced vasodilation in type 2 diabetics with neuropathy
      and elevated triglyceride levels. Omega-3 fatty acids appear to exert beneficial effects on
      vascular function that are independent of the changes in serum triglycerides. The efficacy
      will be compared with a placebo given at the same duration. Efficacy of the drug will be
      evaluated after 3 and 6 months of treatment. This timeline should be adequate for evaluation
      of the primary neurophysiological endpoints. Previously, the investigators have demonstrated
      that it is feasible to pharmacologically alter nerve fiber density in as little as 18 weeks
      and that this correlates with subjective and objective measures of neurovascular function.
      The investigators are predicting an enhancement of post-ischemic hyperemia of the foot
      dorsum, where the dilative mechanism is primarily endothelium-dependent and a similar
      improvement in heat-induced hyperemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot study is a within-subject repeated measures design. This study will compare the
      neurophysiological and vascular responses to placebo and treatment with Lovaza® (omega-3-acid
      ethyl esters, Reliant Pharmaceuticals, Inc.) in subjects with type 2 diabetes, neuropathy,
      and dyslipidemia.

      Lovaza's potential mechanism of action is the inhibition of acyl Coenzyme A:1,
      2-diacylglycerol acyltransferase and increased peroxisomal β-oxidation in the liver.

      Subjects will be recruited and a baseline of physiological, neurological and hematological
      profile established for each patient. Forty-four subjects (20 in the active arm, 20 in the
      placebo arm, and 2 replacements for each arm) will receive 4 g/day Lovaza® tablets or placebo
      for a period of 6 months. All subjects will receive a physical and neurological exam as well
      as neurovascular function testing. This includes nerve conduction studies, quantitative
      sensory testing, quantitative autonomic testing, and skin blood flow testing, which includes,
      ischemia reperfusion. Lab tests include an insulin resistance profile, hepatic and renal
      function profiles, lipid profile, C-reactive protein, thyroid stimulating hormone, and fatty
      acids. Other tests include inflammatory markers such as adiponectin and tumor necrosis
      factor-α. The study is powered to detect differences in microvascular function after 6 months
      of Lovaza® and differences in ethnic responses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in Conduction Amplitude.</measure>
    <time_frame>One year</time_frame>
    <description>19 participants in each arm( placebo or omega-3-ethyl esters 4g) were analyzed . Conduction velocities and amplitude of the following nerves were compared between each arm: Tibial Nerve Ankle Amplitude, Tibial Nerve Popliteal Amplitude, Median Nerve Wrist Amplitude, Median Nerve Elbow Amplitude, Peroneal Motor Nerve Ankle Amplitude, Peroneal Motor Nerve Below Fibular Amplitude, Peroneal Motor Nerve Above Fibular Amplitude, Sensory Median Nerve Wrist Amplitude, Sensory Ulnar, Sensory Sural Ankle Ampltiude Wrist Ampltiude</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurements of Indices of Large and Small Fiber Nerve Function Including Heart Rate Variation Measures.</measure>
    <time_frame>One year</time_frame>
    <description>Quantitative Autonomic Function Tests (QAFTs) were performed. Primarily, power spectral analysis of heart rate variability (HRV) and time- and frequency-domain analyses, including measures of the sympathetic and parasympathetic control of the heart beat (R-R interval), were recorded with deep breathing, Valsalva, and standing from the sitting position maneuvers. Additionally, the sample difference of the beat to beat (NN) intervals and the TSP was calculated as well as the standard deviation of all normal R-R intervals (sdNN).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurements of Indices of Large and Small Fiber Nerve Function Using Vibration and Thermal Thresholds.</measure>
    <time_frame>One year</time_frame>
    <description>Quantitative Sensory Tests (QSTs), including, cold sensation threshold, cold pain threshold and vibration detection threshold, were used to evaluate peripheral sensory perception.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change in Measurements of Indices of Large and Small Fiber Nerve Function Including Vibration Thresholds</measure>
    <time_frame>One year</time_frame>
    <description>Quantitative Sensory Tests (QSTs), including vibration detection threshold, were used to evaluate peripheral sensory perception. Mean represents percent change of total group. Measurements taken at baseline and at one year.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurements of Indices of Large and Small Fiber Nerve Function Including Markers of Inflammation and Oxidative Stress.</measure>
    <time_frame>One year</time_frame>
    <description>Oxidative stress/inflammatory markers (IL1β, IKKβ, TLR4, TNF-α, JNK1, toll-like receptor 2) were assessed through a meal challenge.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy Measures Are Nerve Conduction Studies; Specifically, Increases in Conduction Velocity.</measure>
    <time_frame>One Year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in Latency.</measure>
    <time_frame>One Year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in F-wave Conduction</measure>
    <time_frame>One Year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy Measures Examining Increased Vascular Response to Ischemic Block and to Local Warming at the Dorsum of the Foot.</measure>
    <time_frame>One Year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <condition>Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omega-3-ethyl esters 4g</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omega-3-ethyl esters</intervention_name>
    <description>Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (&gt;500 mg/dL) triglyceride (TG) levels in adult patients.</description>
    <arm_group_label>omega-3-ethyl esters 4g</arm_group_label>
    <other_name>Lovaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects may be males or non-pregnant, non-lactating females age 18-80 years.

          2. Subjects must have been diagnosed with type 2 diabetes mellitus according to the
             current ADA criteria.

          3. Triglyceride levels above 149 mg/dL

          4. Minimum of 2 years after diagnosis of type 2 diabetes

          5. Prior to participation in this study, each subject must sign an informed consent
             document.

        Exclusion Criteria:

          1. Presence of type 1 diabetes mellitus (defined as C-peptide &lt; 1 ng/ml or diabetes onset
             at &lt; 35 years of age in a non-obese patient).

          2. Presence of diabetic retinopathy that is more severe than &quot;background&quot; level.

          3. Presence of diabetic nephropathy, defined by urine dipstick results greater than 300
             mg/100 mL for protein (proteinuria).

          4. Presence of clinically significant neuropathy that is clearly of non-diabetic origin,
             e.g. alcoholic or autoimmune.

          5. Bilateral amputation of lower extremities or foot ulcers involving the great toes.
             Presence of neuroarthropathy (Charcot deformity) is allowable.

          6. History of major macrovascular events such as myocardial infarction or stroke.

          7. Participation in another clinical trial concurrently or within 30 days prior to entry
             into this study.

          8. The use of ACE-inhibiting agents or angiotensin receptor blockade therapy (ARB) is
             allowed but must have been stable for at least 30 days prior to study entry and may
             not change during the course of the study. This is prudent due to their potential
             effects on blood flow.

          9. Patients with moderate or severe hepatic insufficiency or abnormalities of liver
             function defined as any liver enzymes (aspartate aminotransferase,alanine
             transaminase, alkaline phosphatase) greater than 3 times the upper limit of normal.

         10. Presence of pedal edema.

         11. Presence or history of heart failure New York Heart Association Class II or greater.

         12. Other serious medical conditions that in the opinion of the investigator, would
             compromise the subject's participation in the study.

         13. Concomitant use of medications known to exacerbate triglyceride levels, such as
             estrogens.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron I Vinik, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Virginia Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henri K Parson, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Eastern Virgina Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Strelitz Diabetes Center</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2009</study_first_submitted>
  <study_first_submitted_qc>June 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2009</study_first_posted>
  <results_first_submitted>February 4, 2016</results_first_submitted>
  <results_first_submitted_qc>March 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 9, 2017</results_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eastern Virginia Medical School</investigator_affiliation>
    <investigator_full_name>Aaron I. Vinik, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
Placebo: Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Lovaza</title>
          <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months.
omega-3-acie ethyl esters: Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (&gt;500 mg/dL) triglyceride (TG) levels in adult patients.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The study was powered at 0.80 for a two-tail analysis with a sensitivity of a 30% delta in blood flow in 40 subjects. The standard deviation of the measurements was calculated at 45% of the treatment group mean. This assessment of variance could accommodate for 9% attrition or data loss in the study. 44 patients will be recruited in total.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
Placebo: Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.</description>
        </group>
        <group group_id="B2">
          <title>Lovaza</title>
          <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months.
omega-3-acie ethyl esters: Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (&gt;500 mg/dL) triglyceride (TG) levels in adult patients.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.58" spread="2.06"/>
                    <measurement group_id="B2" value="58.21" spread="1.70"/>
                    <measurement group_id="B3" value="59.39" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (lbs)</title>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="217.03" spread="9.62"/>
                    <measurement group_id="B2" value="215.16" spread="10.38"/>
                    <measurement group_id="B3" value="215.71" spread="7.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI kg/m^2</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.04" spread="1.17"/>
                    <measurement group_id="B2" value="34.37" spread="1.83"/>
                    <measurement group_id="B3" value="34.10" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Qualifying triglyceride level (mg/dL)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="215.05" spread="12.51"/>
                    <measurement group_id="B2" value="261.17" spread="50.73"/>
                    <measurement group_id="B3" value="237.48" spread="24.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total cholesterol (mg/dL)</title>
          <units>(mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="152.26" spread="6.56"/>
                    <measurement group_id="B2" value="189.42" spread="9.63"/>
                    <measurement group_id="B3" value="170.84" spread="6.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HDL cholesterol (mg/dL)</title>
          <units>(mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.84" spread="2.27"/>
                    <measurement group_id="B2" value="43.32" spread="2.81"/>
                    <measurement group_id="B3" value="41.58" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL cholesterol (mg/dL)</title>
          <units>(mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.84" spread="5.80"/>
                    <measurement group_id="B2" value="101.44" spread="7.21"/>
                    <measurement group_id="B3" value="88.30" spread="5.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c (%)</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.82" spread="0.35"/>
                    <measurement group_id="B2" value="7.66" spread="0.23"/>
                    <measurement group_id="B3" value="7.73" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting glucose (mg/dL)</title>
          <units>(mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155.89" spread="9.18"/>
                    <measurement group_id="B2" value="157.21" spread="12.09"/>
                    <measurement group_id="B3" value="156.55" spread="7.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>serum glutamate oxaloacetate transaminase(AST) (u/L)</title>
          <units>(u/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.16" spread="1.50"/>
                    <measurement group_id="B2" value="24.11" spread="2.28"/>
                    <measurement group_id="B3" value="24.00" spread="8.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>serum glutamate pyruvate transaminase (ALT) (u/L)</title>
          <units>(u/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.79" spread="2.63"/>
                    <measurement group_id="B2" value="31.05" spread="3.84"/>
                    <measurement group_id="B3" value="30.71" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alkaline phosphatase (u/L)</title>
          <units>(u/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.89" spread="6.55"/>
                    <measurement group_id="B2" value="70.11" spread="4.40"/>
                    <measurement group_id="B3" value="74.63" spread="4.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-peptide (ng/mL)</title>
          <units>(ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.66" spread="0.40"/>
                    <measurement group_id="B2" value="4.56" spread="0.45"/>
                    <measurement group_id="B3" value="4.61" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin (uIU/mL)</title>
          <units>(uIU/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.54" spread="12.63"/>
                    <measurement group_id="B2" value="26.23" spread="5.88"/>
                    <measurement group_id="B3" value="32.88" spread="6.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in Conduction Amplitude.</title>
        <description>19 participants in each arm( placebo or omega-3-ethyl esters 4g) were analyzed . Conduction velocities and amplitude of the following nerves were compared between each arm: Tibial Nerve Ankle Amplitude, Tibial Nerve Popliteal Amplitude, Median Nerve Wrist Amplitude, Median Nerve Elbow Amplitude, Peroneal Motor Nerve Ankle Amplitude, Peroneal Motor Nerve Below Fibular Amplitude, Peroneal Motor Nerve Above Fibular Amplitude, Sensory Median Nerve Wrist Amplitude, Sensory Ulnar, Sensory Sural Ankle Ampltiude Wrist Ampltiude</description>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
Placebo: Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Omega-3-ethyl Esters 4g</title>
            <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months.
omega-3-ethyl esters: Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (&gt;500 mg/dL) triglyceride (TG) levels in adult patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in Conduction Amplitude.</title>
          <description>19 participants in each arm( placebo or omega-3-ethyl esters 4g) were analyzed . Conduction velocities and amplitude of the following nerves were compared between each arm: Tibial Nerve Ankle Amplitude, Tibial Nerve Popliteal Amplitude, Median Nerve Wrist Amplitude, Median Nerve Elbow Amplitude, Peroneal Motor Nerve Ankle Amplitude, Peroneal Motor Nerve Below Fibular Amplitude, Peroneal Motor Nerve Above Fibular Amplitude, Sensory Median Nerve Wrist Amplitude, Sensory Ulnar, Sensory Sural Ankle Ampltiude Wrist Ampltiude</description>
          <units>uV</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tibial Nerve Ankle Amplitude</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.28" spread="0.94"/>
                    <measurement group_id="O2" value="7.14" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tibial Nerve Popliteal Amplitude</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.08" spread="0.58"/>
                    <measurement group_id="O2" value="3.80" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median Nerve Wrist Amplitude</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.89" spread="0.60"/>
                    <measurement group_id="O2" value="7.24" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median Nerve Elbow Amplitude</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.21" spread="0.56"/>
                    <measurement group_id="O2" value="6.06" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peroneal Motor Nerve Ankle Amplitude</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.97" spread="0.47"/>
                    <measurement group_id="O2" value="2.55" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peroneal Motor Nerve Below Fibular Amplitude</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70" spread="0.46"/>
                    <measurement group_id="O2" value="2.17" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peroneal Motor Nerve Above Fibular Amplitude</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" spread="0.46"/>
                    <measurement group_id="O2" value="2.11" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensory Median Nerve Wrist Amplitude</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.96" spread="3.04"/>
                    <measurement group_id="O2" value="26.56" spread="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensory Ulnar Wrist Ampltiude</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.93" spread="3.39"/>
                    <measurement group_id="O2" value="21.65" spread="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensory Sural Ankle Ampltiude</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.01" spread="1.55"/>
                    <measurement group_id="O2" value="8.33" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measurements of Indices of Large and Small Fiber Nerve Function Including Heart Rate Variation Measures.</title>
        <description>Quantitative Autonomic Function Tests (QAFTs) were performed. Primarily, power spectral analysis of heart rate variability (HRV) and time- and frequency-domain analyses, including measures of the sympathetic and parasympathetic control of the heart beat (R-R interval), were recorded with deep breathing, Valsalva, and standing from the sitting position maneuvers. Additionally, the sample difference of the beat to beat (NN) intervals and the TSP was calculated as well as the standard deviation of all normal R-R intervals (sdNN).</description>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
Placebo: Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Lovaza</title>
            <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months.
omega-3-acie ethyl esters: Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (&gt;500 mg/dL) triglyceride (TG) levels in adult patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurements of Indices of Large and Small Fiber Nerve Function Including Heart Rate Variation Measures.</title>
          <description>Quantitative Autonomic Function Tests (QAFTs) were performed. Primarily, power spectral analysis of heart rate variability (HRV) and time- and frequency-domain analyses, including measures of the sympathetic and parasympathetic control of the heart beat (R-R interval), were recorded with deep breathing, Valsalva, and standing from the sitting position maneuvers. Additionally, the sample difference of the beat to beat (NN) intervals and the TSP was calculated as well as the standard deviation of all normal R-R intervals (sdNN).</description>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Resting sdNN (ms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.924" spread="15.509"/>
                    <measurement group_id="O2" value="40.748" spread="16.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resting rmsSD (ms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.838" spread="15.592"/>
                    <measurement group_id="O2" value="72.075" spread="30.165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deep Breathing sdNN (ms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.840" spread="10.703"/>
                    <measurement group_id="O2" value="11.637" spread="11.426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deep Breathing rmsSD (ms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.823" spread="2.462"/>
                    <measurement group_id="O2" value="38.136" spread="10.539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valsalva sdNN (ms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.136" spread="0.077"/>
                    <measurement group_id="O2" value="6.333" spread="13.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valsalva rmsSD (ms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.752" spread="15.511"/>
                    <measurement group_id="O2" value="26.668" spread="20.514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing sdNN (ms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3786" spread="10.361"/>
                    <measurement group_id="O2" value="8.622" spread="12.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing rmsSD (ms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.725" spread="20.551"/>
                    <measurement group_id="O2" value="38.243" spread="21.850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measurements of Indices of Large and Small Fiber Nerve Function Using Vibration and Thermal Thresholds.</title>
        <description>Quantitative Sensory Tests (QSTs), including, cold sensation threshold, cold pain threshold and vibration detection threshold, were used to evaluate peripheral sensory perception.</description>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
Placebo: Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Omega-3-ethyl Esters 4g</title>
            <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months.
omega-3-ethyl esters: Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (&gt;500 mg/dL) triglyceride (TG) levels in adult patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurements of Indices of Large and Small Fiber Nerve Function Using Vibration and Thermal Thresholds.</title>
          <description>Quantitative Sensory Tests (QSTs), including, cold sensation threshold, cold pain threshold and vibration detection threshold, were used to evaluate peripheral sensory perception.</description>
          <units>°C</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cold Sensation Threshold-Finger (°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.311" spread="0.469"/>
                    <measurement group_id="O2" value="0.221" spread="0.749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cold Pain Threshold-Finger (°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.167" spread="1.525"/>
                    <measurement group_id="O2" value="-1.789" spread="1.882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cold Sesnation Threshold-Toe (°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.169" spread="1.183"/>
                    <measurement group_id="O2" value="-3.763" spread="1.647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cold Pain Threshold-Toe (°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.658" spread="1.906"/>
                    <measurement group_id="O2" value="-1.405" spread="2.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cold Sensation Threshold-Dorsum (°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.062" spread="1.484"/>
                    <measurement group_id="O2" value="-3.768" spread="1.709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cold Pain Threshold-Dorsum (°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.937" spread="2.215"/>
                    <measurement group_id="O2" value="-1.739" spread="2.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Measurements of Indices of Large and Small Fiber Nerve Function Including Vibration Thresholds</title>
        <description>Quantitative Sensory Tests (QSTs), including vibration detection threshold, were used to evaluate peripheral sensory perception. Mean represents percent change of total group. Measurements taken at baseline and at one year.</description>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
Placebo: Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Omega-3-ethyl Esters 4g</title>
            <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months.
omega-3-ethyl esters: Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (&gt;500 mg/dL) triglyceride (TG) levels in adult patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Measurements of Indices of Large and Small Fiber Nerve Function Including Vibration Thresholds</title>
          <description>Quantitative Sensory Tests (QSTs), including vibration detection threshold, were used to evaluate peripheral sensory perception. Mean represents percent change of total group. Measurements taken at baseline and at one year.</description>
          <units>% Change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vibration Detection Threshold-Finger (% Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.375" spread="0.241"/>
                    <measurement group_id="O2" value="-1.102" spread="0.309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vibration Detection Threshold-Toe (% Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.750" spread="5.321"/>
                    <measurement group_id="O2" value="-8.169" spread="3.263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measurements of Indices of Large and Small Fiber Nerve Function Including Markers of Inflammation and Oxidative Stress.</title>
        <description>Oxidative stress/inflammatory markers (IL1β, IKKβ, TLR4, TNF-α, JNK1, toll-like receptor 2) were assessed through a meal challenge.</description>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
Placebo: Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Omega-3-ethyl Esters 4g</title>
            <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months.
omega-3-ethyl esters: Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (&gt;500 mg/dL) triglyceride (TG) levels in adult patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurements of Indices of Large and Small Fiber Nerve Function Including Markers of Inflammation and Oxidative Stress.</title>
          <description>Oxidative stress/inflammatory markers (IL1β, IKKβ, TLR4, TNF-α, JNK1, toll-like receptor 2) were assessed through a meal challenge.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL1β (pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.21"/>
                    <measurement group_id="O2" value="1.14" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IKKβ (pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="0.16"/>
                    <measurement group_id="O2" value="0.96" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLR4 (pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="0.18"/>
                    <measurement group_id="O2" value="1.17" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFα (pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" spread="0.19"/>
                    <measurement group_id="O2" value="0.76" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JNK1 (pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="0.15"/>
                    <measurement group_id="O2" value="0.75" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>toll-like receptor 2 (pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.12"/>
                    <measurement group_id="O2" value="0.87" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy Measures Are Nerve Conduction Studies; Specifically, Increases in Conduction Velocity.</title>
        <time_frame>One Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
Placebo: Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Omega-3-ethyl Esters 4g</title>
            <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months.
omega-3-ethyl esters: Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (&gt;500 mg/dL) triglyceride (TG) levels in adult patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Measures Are Nerve Conduction Studies; Specifically, Increases in Conduction Velocity.</title>
          <units>m/s</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tibial Nerve Popliteal Conduction Velocity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.08" spread="6.58"/>
                    <measurement group_id="O2" value="37.53" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median Nerve Elbow Conduction Velocity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.89" spread="1.76"/>
                    <measurement group_id="O2" value="46.74" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peroneal Motor Nerve Bel. Fib. Conduction Velocity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.36" spread="1.35"/>
                    <measurement group_id="O2" value="39.96" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peroneal Motor Nerve Abo. Fib. Conduction Velocity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.44" spread="3.65"/>
                    <measurement group_id="O2" value="45.00" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensory Median Nerve Wrist Conduction Velocity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.76" spread="3.08"/>
                    <measurement group_id="O2" value="46.59" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensory Ulnar Wrist Conduction Velocity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.94" spread="1.73"/>
                    <measurement group_id="O2" value="45.22" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensory Sural Ankle Conduction Velocity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.03" spread="1.61"/>
                    <measurement group_id="O2" value="38.60" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in Latency.</title>
        <time_frame>One Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
Placebo: Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Omega-3-ethyl Esters 4g</title>
            <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months.
omega-3-ethyl esters: Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (&gt;500 mg/dL) triglyceride (TG) levels in adult patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in Latency.</title>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tibial Nerve Ankle Latency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.08" spread="0.28"/>
                    <measurement group_id="O2" value="5.29" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tibial Nerve Popliteal Latency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.65" spread="0.51"/>
                    <measurement group_id="O2" value="16.41" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median Nerve Wrist Latency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.81" spread="1.15"/>
                    <measurement group_id="O2" value="4.56" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median Nerve Elbow Latency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.16" spread="0.43"/>
                    <measurement group_id="O2" value="8.79" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peroneal Motor Nerve Ankle Latency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.77" spread="0.49"/>
                    <measurement group_id="O2" value="5.24" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peroneal Motor Nerve Below Fibular Latency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.58" spread="0.77"/>
                    <measurement group_id="O2" value="13.20" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peroneal Motor Nerve Above Fibular Latency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.37" spread="0.95"/>
                    <measurement group_id="O2" value="14.92" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensory Median Nerve Wrist Latency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.48" spread="0.33"/>
                    <measurement group_id="O2" value="3.01" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensory Ulnar Wrist Latency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.51" spread="0.13"/>
                    <measurement group_id="O2" value="2.62" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensory Sural Ankle Latency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68" spread="0.15"/>
                    <measurement group_id="O2" value="3.70" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in F-wave Conduction</title>
        <time_frame>One Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
Placebo: Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Omega-3-ethyl Esters 4g</title>
            <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months.
omega-3-ethyl esters: Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (&gt;500 mg/dL) triglyceride (TG) levels in adult patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in F-wave Conduction</title>
          <units>m/s</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tibial Nerve F-Wave Conduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.14" spread="3.02"/>
                    <measurement group_id="O2" value="55.89" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median Nerve F-Wave Conduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.46" spread="1.09"/>
                    <measurement group_id="O2" value="29.44" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peroneal Motor Nerve F-Wave Conduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.96" spread="3.09"/>
                    <measurement group_id="O2" value="47.47" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy Measures Examining Increased Vascular Response to Ischemic Block and to Local Warming at the Dorsum of the Foot.</title>
        <time_frame>One Year</time_frame>
        <population>Measures of vascular response to ischemic block and local warming at the dorsum of the foot were not reliably collected for this assessment due to the difficulty of analysis and the inability to properly distinguish a vascular response in patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
Placebo: Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Omega-3-ethyl Esters 4g</title>
            <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months.
omega-3-ethyl esters: Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (&gt;500 mg/dL) triglyceride (TG) levels in adult patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Measures Examining Increased Vascular Response to Ischemic Block and to Local Warming at the Dorsum of the Foot.</title>
          <population>Measures of vascular response to ischemic block and local warming at the dorsum of the foot were not reliably collected for this assessment due to the difficulty of analysis and the inability to properly distinguish a vascular response in patients.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse event data was collected per individual from time of consent to 6 months after consent.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
Placebo: Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Lovaza</title>
          <description>Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months.
omega-3-acie ethyl esters: Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (&gt;500 mg/dL) triglyceride (TG) levels in adult patients.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitilization due to low blood pressure and fainting</sub_title>
                <description>Patient passed out in home, ER recorded BP as 63/48. During ER stay, patient had an EKG, MRI, ultrasound, and carotid doppler tests which all proved to be normal. Cause of fainting undetermined.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Overnight stay in ER for observation after experiencing chest pain</sub_title>
                <description>Patient seen in ER after reporting feeling pain in chest that &quot;radiated down her arm&quot; and some pain in her back and abdomen. A nuclear stress test was performed and patient states that no blockages were found.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head trauma due to accidental fall</sub_title>
                <description>Patient fell and suffered bruises and cuts to her face; received more than 25 stitches and wound care to her face. Later, patient experienced vomiting and headaches and later received a CAT scan which displayed an internal head bleed due to trauma.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atypical Chest Pain</sub_title>
                <description>Normal EKG, no evidence of myocardial infarction, normal stress test and echocardiogram and troponin normal</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Planned surgery to treat Achalasia/Esophageal motility disorder</sub_title>
                <description>Patient underwent a planned surgical procedure to treat Achalasia/Esophageal motility disorder. Procedure lasted 6 hours, and patient was under anesthesia for 7 hours. This was an in-patient procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Emergency Surgery to relieve bile duct obstruction</sub_title>
                <description>Patient went to ER reporting abdominal pain, losing 6 pounds, dark urine and clay-colored stool.CT scan found 2 stones in gallbladder - 1 occluding the common bile duct. An Endoscopic Retrograde Cholangiopancreatography removed both offending stones.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>Patients reports consistent higher than normal blood glucose levels. Patient instructed to continue to monitor levels.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Discharge</sub_title>
                <description>Patient reports experiencing significant increases in eye discharge. Patient reports seeing an ophthalmologist with no significant abnormalities noted.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dry/Achy Eyes</sub_title>
                <description>Patient reports experiencing increased eye strain and very dry eyes. Patient seen at ophthalmologist; prescribed artificial tears to be take Q 4 hours.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Severe-Moderate Diarrhea</sub_title>
                <description>Patient experienced severe to moderate diarrhea which was explained as &quot;uncontrollable&quot; at times</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dehyrdation/Severe Vomiting/Diarrhea</sub_title>
                <description>Patient went to ER for severe dehydration (administered 2 IV bags) and nausea (given Zofran). Patient went back to ER two weeks later for similar symptoms. Dehydration most likely due to vomiting and severe diarrhea</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <description>Patient reports experiencing lower left quadrant pain with increased night sweats and low-grade fever. Patient seen at ER, where CAT scan revealed swollen lymph nodes in the small mesenteric bowel.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial Infection</sub_title>
                <description>Patient reports a bacterial infection and rash on abdomen and chest. Seen at dermatologist and prescribed prescription body wash, Z-pack, and skin culture.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Personal Injury</sub_title>
                <description>Patient slipped in shower and struck right elbow against the shower wall. Patient seen at ER, where x-rays revealed no abnormalities.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Personal Injury</sub_title>
                <description>Rising from a seated position, patient fell. No dizziness, shortness of breath, or blurred vision noted. Patient did not receive any further medical attention.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Upper limb weakness</sub_title>
                <description>Patient reports increased arm pain/weakness bilaterally. Ordered nerve conduction study on median, ulnar, and radial nerves bilaterally resulting in otherwise normal results.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <description>Patient reports experiencing increased lower back pain. Went to ER, where x-rays revealed no significant findings. Pain attributed to soft tissue injury due to overactivity or arthritis. Received two shots of Dilaudid.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness/Fainting</sub_title>
                <description>While stopped at red light, patient reports feeling dizzy and then fainting causing her to strike another car. Bloodwork/CT done at ER with normal results. Cause of fainting undetermined.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fainting/Dizziness</sub_title>
                <description>While exiting a vehicle, patient reports fainting (no dizziness reported). Cause of fainting unknown.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Bells Palsy</sub_title>
                <description>During routine physical, patient showed signs and symptoms of having Bells Palsy. Patient also reports being recently diagnosed with genital herpes. Patient prescribed metrozol pack and valtrex.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <description>Patient administered 5-day Z-pack; all symptoms subsided</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>Patient suffered asthma-related bronchitis; prescribed prednisone, antibiotic, and inhaler.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cranial/Facial Lesions</sub_title>
                <description>Patients reports sores on scalp and unhealing dark spots on facial skin. Patients also reports &quot;stabbing&quot; pain in left knee and left side of foot.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bladder Suspension with Sling</sub_title>
                <description>Patient underwent cystoscopy with transobturator sling. Not considered an emergency surgery.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Henri Parson</name_or_title>
      <organization>Eastern Virginia Medical School</organization>
      <phone>(757)446-7976</phone>
      <email>parsonhk@evms.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

